Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report

REFERENCES

• Cozzolino M, Brancaccio D, Gallieni M, . Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol. 2005;18:5–8.
   PubMed Web of Science ®Google Scholar
• Andress DL, Norris KC, Coburn JW, . Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Eng J Med. 1989;321:274–279.
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Searon TE, Levin NW, . Association of serum phosphate and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617.
   PubMed Web of Science ®Google Scholar
• Foley RN, Murray AM, Li S, . Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–495.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Levin A, Levin NW. NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):1–201.
   Google Scholar
• Johnson DW, Pollock CA, MacDougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007;12:321–330.
   PubMed Web of Science ®Google Scholar
• Akmal M, Telfer N, Ansari AN, . Erythrocyte survival in chronic renal failure. Role of secondary hyperparathyroidism. J Clin Invest. 1985;76:1695–1698.
   PubMed Web of Science ®Google Scholar
• Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16(Suppl. 7):25–28.
   PubMed Web of Science ®Google Scholar
• Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin Dial. 2006;19:146–151.
   PubMed Web of Science ®Google Scholar
• Messa PG, Macário F, Yaqoob M, . The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36–45.
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco AL, . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525.
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, . Cinacalcet HCL, an oral calciomimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807.
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Coburn JW, . Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int. 2005;67:760–771.
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olsonm K, . Effect of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800.
   PubMed Web of Science ®Google Scholar
• Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: A combined therapeutic approach. J Am Soc Nephrol. 2004;15:S21–S24.
   PubMed Web of Science ®Google Scholar
• Washio M, Iseki K, Onayoma K, . Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic hemodialysis patients. Nephrol DialTransplant. 1992;7:121–124.
   PubMed Web of Science ®Google Scholar
• Meytes D, Bogin E, Ma A, . Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981;67:1263–1269.
   PubMed Web of Science ®Google Scholar
• McGonigle RJ, Wallin JD, Husserl F, . Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med. 1984;104:1016–1026.
   PubMed Web of Science ®Google Scholar
• Bogin E, Massry SG, Levi J, . Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest. 1982;69:1017–1025.
   PubMed Web of Science ®Google Scholar
• Drueke T. R-HuEpo hyporesponsiveness – Who and why. Nephrol Dial Transplant. 1995;10(Suppl. 2):62–68.
   PubMedGoogle Scholar
• Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328:171–175.
   PubMed Web of Science ®Google Scholar
• Mandolfo S, Malberti F, Farina M, . Parathyroidectomy and response to erythropoietin therapy in anemic patients with chronic renal failure. Nephrol Dial Transplant. 1998;13:2708–2709.
   PubMed Web of Science ®Google Scholar
• Chow TL, Chan TT, Ho YW, . Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg. 2007;142:644–648.
   PubMedGoogle Scholar
• Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009;24:571–579.
   PubMed Web of Science ®Google Scholar
• Al-Hilali N, Al-Humoud H, Ninan VT, . Does parathyroid hormone affect erythropoietin therapy in dialysis patients? Med Princ Pract. 2007;16:63–67.
   PubMed Web of Science ®Google Scholar
• Viana H, Vila Lobos A, Resina C, . Treatment of secondary hyperparathyroidism with cinacalcet is associated with an increase in hemoglobin levels. Port J Nephrol Hypert. 2007;21:225–229.
   Google Scholar
• Torres PS, Borrego Utiel FJ, Sánchez Perales MC, . Analysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in hemodialysis patients. Nefrologia. 2010;30:443–451.
   PubMed Web of Science ®Google Scholar
• Matias PJ, Jorge C, Ferreira C, . Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5:905–911.
   PubMed Web of Science ®Google Scholar
• Capuano A, Serio V, Pota A, . Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009;22:59–68.
   PubMed Web of Science ®Google Scholar